Windward Bio secured $165 million for clinical trials targeting respiratory diseases, according to the company’s financing announcement. The round will support a lead program in respiratory disorders and a second program with potential applications in respiratory and dermatological indications. Both pipeline assets are described as long-acting antibodies designed to compete on dosing convenience versus currently available biologics. The funding size underscores continued appetite for next-generation antibody platforms in respiratory inflammation and immunology-led development. For biotech strategists, the financing is a reminder that capital is concentrating on late de-risking milestones—especially when long-acting differentiation can translate into improved patient adherence and health economics.